Rapid diagnostic test accessibility considerations for professional use and self-tests

This document contains considerations for ensuring accessibility and usability of rapid diagnostic tests (RDTs) and their components by all users.
The scope of the document encompasses rapid diagnostics for both professional use and self-testing, including, but not limited to, HIV, P. falciparum/vivax malaria, tuberculosis, SARS-CoV-2, syphilis, hepatitis B, hepatitis C, urine dipstick, G6PD, and pregnancy.
RDT developers and manufacturers, regulatory agencies, procurement agencies, implementing partners, donors and funders of diagnostic research and diagnostic innovations, have an incentive to ensure that diagnostics can be useable by everyone who need them.